Investigational drug · Phase 3
Olvi-Vec
Also called: olvimulogene nanivacirepvec, GL-ONC, GLV-1h68
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "Olvi-Vec"
First trial start
2022
Aug 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olvi-Vec", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
- SCLC, Extensive Stage
- Platinum-resistant Ovarian Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Olvi-Vec" as an intervention, largest first.
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Pivotal-lookingRecruiting
Genelux CorporationIndustry
NCT05281471 · 186 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 2026
Drug: olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin (preferred) or cisplatin and 2 more · For: Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer and 4 more
Sites: Mobile, Alabama; Tucson, Arizona; Duarte, California · 33 sites in all
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPivotal-lookingRecruiting
Genelux CorporationIndustry
NCT06463665 · 142 participants (planned) · Start Sep 26, 2024 · Primary completion Feb 2027
Drug: Olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin or cisplatin and 3 more · For: Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer and 5 more
Sites: Bullhead City, Arizona; Clermont, Florida; Coral Springs, Florida · 15 sites in all
Genelux CorporationIndustry
NCT02759588 · 46 participants · Start May 2016 · Primary completion Dec 31, 2021
Drug: Olvi-Vec; Platinum-doublet with or without bevacizumab · For: Ovarian Cancer; Peritoneal Carcinomatosis; Fallopian Tube Cancer
Sites: Newport Beach, California; Orlando, Florida
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.Industry
NCT07136285 · 27 participants (planned) · Start Jul 24, 2023 · Primary completion Dec 2026
Drug: Olvi-Vec; platinum (cisplatin or carboplatin) and 1 more · For: SCLC, Extensive Stage
Sites: Hangzhou, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report.
Chen Y, Qin ZQ, Li ZM, et al. · Front Oncol 2026
- Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy.
D'Arcy A, Ferguson BJ · Immunol Lett 2026
- Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.
Yu YA, Holloway RW, Mendivil AA, et al. · Gynecol Oncol Rep 2026
- A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, et al. · Int J Gynecol Cancer 2023
- Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW, Mendivil AA, Kendrick JE, et al. · JAMA Oncol 2023
- Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
Chintala NK, Choe JK, McGee E, et al. · Front Immunol 2023
Also in development for Advanced Non-squamous Non-small-cell Lung Cancer
- JAB-3312Phase 32 trials
Allist Pharmaceuticals, Inc. · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.